loading
Schlusskurs vom Vortag:
$88.82
Offen:
$88.31
24-Stunden-Volumen:
4.91M
Relative Volume:
0.86
Marktkapitalisierung:
$111.37B
Einnahmen:
$27.80B
Nettoeinkommen (Verlust:
$1.05B
KGV:
20.58
EPS:
4.35
Netto-Cashflow:
$6.90B
1W Leistung:
+0.57%
1M Leistung:
+6.64%
6M Leistung:
+36.64%
1J Leistung:
+11.62%
1-Tages-Spanne:
Value
$88.19
$89.57
1-Wochen-Bereich:
Value
$86.81
$89.57
52-Wochen-Spanne:
Value
$62.07
$89.74

Gilead Sciences Inc Stock (GILD) Company Profile

Name
Firmenname
Gilead Sciences Inc
Name
Telefon
(650) 574-3000
Name
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Name
Mitarbeiter
18,000
Name
Twitter
@GileadSciences
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
GILD's Discussions on Twitter

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2023-11-09 Eingeleitet Deutsche Bank Hold
2023-09-08 Hochstufung BofA Securities Neutral → Buy
2023-09-06 Eingeleitet HSBC Securities Reduce
2023-07-24 Bestätigt Barclays Equal Weight
2023-05-16 Hochstufung BMO Capital Markets Market Perform → Outperform
2023-04-28 Fortgesetzt Piper Sandler Overweight
2023-01-03 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2022-12-13 Fortgesetzt BofA Securities Neutral
2022-12-09 Herabstufung DZ Bank Buy → Hold
2022-10-31 Hochstufung Barclays Underweight → Equal Weight
2022-10-28 Bestätigt BMO Capital Markets Market Perform
2022-10-28 Bestätigt Cowen Outperform
2022-10-28 Bestätigt JP Morgan Overweight
2022-10-28 Bestätigt Jefferies Buy
2022-10-28 Hochstufung Piper Sandler Neutral → Overweight
2022-10-28 Bestätigt RBC Capital Mkts Outperform
2022-10-28 Hochstufung Truist Hold → Buy
2022-10-28 Bestätigt Wells Fargo Equal Weight
2022-10-04 Hochstufung JP Morgan Neutral → Overweight
2022-07-13 Eingeleitet Cantor Fitzgerald Neutral
2022-05-23 Eingeleitet SVB Leerink Mkt Perform
2022-02-28 Herabstufung BMO Capital Markets Outperform → Market Perform
2022-02-02 Bestätigt BMO Capital Markets Outperform
2022-02-02 Bestätigt BofA Securities Neutral
2022-02-02 Bestätigt RBC Capital Mkts Outperform
2022-02-02 Bestätigt Truist Hold
2022-02-02 Bestätigt Wells Fargo Equal Weight
2022-01-28 Hochstufung Argus Hold → Buy
2022-01-06 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-12-09 Fortgesetzt Wells Fargo Equal Weight
2021-12-06 Eingeleitet Goldman Neutral
2021-11-19 Hochstufung BMO Capital Markets Market Perform → Outperform
2021-11-19 Fortgesetzt Piper Sandler Neutral
2021-10-20 Fortgesetzt Cowen Outperform
2021-07-30 Bestätigt BMO Capital Markets Market Perform
2021-07-30 Bestätigt RBC Capital Mkts Outperform
2021-04-01 Hochstufung Bernstein Mkt Perform → Outperform
2021-03-30 Hochstufung Redburn Neutral → Buy
2021-01-19 Hochstufung Morgan Stanley Equal-Weight → Overweight
2021-01-04 Hochstufung Guggenheim Neutral → Buy
2020-11-03 Fortgesetzt Morgan Stanley Equal-Weight
2020-10-28 Eingeleitet UBS Neutral
2020-09-30 Fortgesetzt Jefferies Buy
2020-09-15 Hochstufung Maxim Group Hold → Buy
2020-07-31 Bestätigt Credit Suisse Neutral
2020-07-31 Bestätigt Morgan Stanley Equal-Weight
2020-07-31 Bestätigt Piper Sandler Overweight
2020-07-31 Bestätigt RBC Capital Mkts Outperform
2020-07-31 Bestätigt SunTrust Hold
2020-07-31 Bestätigt Wells Fargo Equal Weight
2020-07-20 Hochstufung Credit Suisse Underperform → Neutral
2020-06-03 Hochstufung SVB Leerink Mkt Perform → Outperform
2020-05-26 Hochstufung SunTrust Sell → Hold
2020-05-01 Herabstufung JP Morgan Overweight → Neutral
2020-05-01 Herabstufung Raymond James Outperform → Mkt Perform
2020-05-01 Herabstufung SunTrust Hold → Sell
2020-04-27 Herabstufung UBS Buy → Neutral
2020-04-20 Herabstufung BMO Capital Markets Outperform → Market Perform
2020-04-20 Herabstufung Wells Fargo Overweight → Equal Weight
2020-04-17 Herabstufung CFRA Hold → Sell
Alle ansehen

Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten

pulisher
06:18 AM

Merus annonce ses résultats financiers pour le troisième trimestre 2024 et fait le point sur ses activités - GlobeNewswire Inc.

06:18 AM
pulisher
Nov 01, 2024

Gilead Oncology Grant Supports 22 U.S. Organizations With - CSRwire.com

Nov 01, 2024
pulisher
Nov 01, 2024

Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics - Yahoo Finance

Nov 01, 2024
pulisher
Oct 31, 2024

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know - Yahoo Finance

Oct 31, 2024
pulisher
Oct 31, 2024

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by AustralianSuper Pty Ltd - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Gilead Oncology Grant Supports 22 U.S. Organizations With $3.15 Million to Provide Support to Those Affected By Breast Cancer - Marketscreener.com

Oct 31, 2024
pulisher
Oct 31, 2024

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance

Oct 31, 2024
pulisher
Oct 31, 2024

AbTherx and Gilead Expand Collaboration on Innovative Antibody Discovery Technologies - AccessWire

Oct 31, 2024
pulisher
Oct 30, 2024

Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch

Oct 30, 2024
pulisher
Oct 30, 2024

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by New York State Teachers Retirement System - MarketBeat

Oct 30, 2024
pulisher
Oct 30, 2024

Earnings Preview: Gilead Sciences (GILD) Q3 Earnings Expected to Decline - Yahoo Finance

Oct 30, 2024
pulisher
Oct 30, 2024

Gilead Sciences (GILD) to Release Quarterly Earnings on Wednesday - MarketBeat

Oct 30, 2024
pulisher
Oct 29, 2024

Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why - Yahoo Finance

Oct 29, 2024
pulisher
Oct 29, 2024

Gilead Sciences Inc. stock outperforms competitors despite losses on the day - MarketWatch

Oct 29, 2024
pulisher
Oct 29, 2024

Gilead Sciences (NASDAQ:GILD) Given Sector Perform Rating at Royal Bank of Canada - MarketBeat

Oct 29, 2024
pulisher
Oct 29, 2024

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Nisa Investment Advisors LLC - MarketBeat

Oct 29, 2024
pulisher
Oct 28, 2024

Private Advisor Group LLC Sells 5,794 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat

Oct 28, 2024
pulisher
Oct 27, 2024

GILD (Gilead Sciences) Owner Earnings per Share (TTM) : -1.70 (As of Jun. 2024) - GuruFocus.com

Oct 27, 2024
pulisher
Oct 27, 2024

Hennion & Walsh Asset Management Inc. Sells 7,644 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat

Oct 27, 2024
pulisher
Oct 26, 2024

Gilead Sciences, Inc. (NASDAQ:GILD) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Oct 26, 2024
pulisher
Oct 26, 2024

International Assets Investment Management LLC Buys 1,622,806 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat

Oct 26, 2024
pulisher
Oct 25, 2024

Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 25, 2024
pulisher
Oct 25, 2024

Cullinan Associates Inc. Sells 14,347 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat

Oct 25, 2024
pulisher
Oct 24, 2024

Gilead needs a win with Arcellx CAR-T data. Here’s how to know if it scores - STAT

Oct 24, 2024
pulisher
Oct 23, 2024

Why Gilead Sciences (GILD) Dipped More Than Broader Market Today - Yahoo Finance

Oct 23, 2024
pulisher
Oct 23, 2024

Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Oct 23, 2024
pulisher
Oct 23, 2024

Gilead Sciences (NASDAQ:GILD) Sets New 12-Month HighStill a Buy? - MarketBeat

Oct 23, 2024
pulisher
Oct 23, 2024

Spain CAR-T Cell Therapy Market Forecast to 2029, Featuring - GlobeNewswire

Oct 23, 2024
pulisher
Oct 23, 2024

Lazari Capital Management Inc. Cuts Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat

Oct 23, 2024
pulisher
Oct 22, 2024

Gilead stock touches 52-week high at $87.9 amid robust growth - Investing.com

Oct 22, 2024
pulisher
Oct 22, 2024

Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024 - BioSpace

Oct 22, 2024
pulisher
Oct 22, 2024

Gilead and MSD to advance once-weekly HIV treatment to Phase III - Yahoo Finance

Oct 22, 2024
pulisher
Oct 22, 2024

Gilead Sciences’ Quarterly Earnings Preview: What You Need to Know - Nasdaq

Oct 22, 2024
pulisher
Oct 22, 2024

Gilead Sciences’ Quarterly Earnings Preview: What You Need To Know - Barchart

Oct 22, 2024
pulisher
Oct 22, 2024

Gilead Sciences (NASDAQ:GILD) Stock Rating Upgraded by Leerink Partnrs - MarketBeat

Oct 22, 2024
pulisher
Oct 22, 2024

Creative Planning Grows Stake in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat

Oct 22, 2024
pulisher
Oct 21, 2024

Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks - AOL

Oct 21, 2024
pulisher
Oct 21, 2024

Gilead, MRK Report Data From Investigational Combination Study for HIV - Zacks Investment Research

Oct 21, 2024
pulisher
Oct 21, 2024

Gilead Sciences, Inc. (NASDAQ:GILD) Position Boosted by Bellecapital International Ltd. - MarketBeat

Oct 21, 2024
pulisher
Oct 21, 2024

Gilead upgraded to outperform by Leerink on PrEP outlook (NASDAQ:GILD) - Seeking Alpha

Oct 21, 2024
pulisher
Oct 21, 2024

Gilead and Merck tout first weekly oral HIV treatment - The Pharma Letter

Oct 21, 2024
pulisher
Oct 21, 2024

Gilead retains Outperform rating from BMO Capital - Investing.com India

Oct 21, 2024
pulisher
Oct 21, 2024

Peering Into Gilead Sciences's Recent Short Interest - Benzinga

Oct 21, 2024
pulisher
Oct 21, 2024

Evaluating Gilead Sciences: Insights From 15 Financial Analysts - Benzinga

Oct 21, 2024
pulisher
Oct 21, 2024

Gilead Sciences (NASDAQ:GILD) Upgraded by Leerink Partners to Outperform - MarketBeat

Oct 21, 2024
pulisher
Oct 21, 2024

Gilead to withdraw Trodelvy indication in USA - The Pharma Letter

Oct 21, 2024
pulisher
Oct 21, 2024

Gilead, MSD say HIV combo could be weekly, oral HIV drug - pharmaphorum

Oct 21, 2024
pulisher
Oct 21, 2024

Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48 - BioSpace

Oct 21, 2024
pulisher
Oct 20, 2024

Stratos Investment Management LLC Lowers Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat

Oct 20, 2024
pulisher
Oct 19, 2024

Goldman Sachs: Gilead Sciences, Inc. (NASDAQ:GILD) Is A Stock With High Consensus ROE - Yahoo Finance

Oct 19, 2024

Finanzdaten der Gilead Sciences Inc-Aktie (GILD)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
drug_manufacturers_general SNY
$53.27
price up icon 0.74%
drug_manufacturers_general PFE
$28.09
price down icon 0.74%
$319.22
price down icon 0.29%
drug_manufacturers_general NVS
$109.35
price up icon 0.88%
drug_manufacturers_general MRK
$101.88
price down icon 0.43%
Kapitalisierung:     |  Volumen (24h):